Seagen

TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

Retrieved on: 
Wednesday, December 6, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Capecitabine, Trastuzumab, Senior, Food, Progression-free survival, RECIST, National Comprehensive Cancer Network, Tablet, Breast cancer, Brain, Taxane, Patient, Research and development, PFS, Corr, Division, FDA, Hematology, University, Development, HR, Tucatinib, HER2, Inc., Confidence interval, News, Professor, HIV disease progression rates, Medical imaging, Medicinal plants, Seagen

Seagen Inc. (Nasdaq: SGEN) today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®).

Key Points: 
  • Seagen Inc. (Nasdaq: SGEN) today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®).
  • The combination showed a statistically significant improvement in progression-free survival (PFS), the study’s primary endpoint, in patients with unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2-positive) breast cancer who had been previously treated with trastuzumab and a taxane, compared to those who received placebo plus ado-trastuzumab emtansine.
  • Discontinuations due to adverse events were more common in the combination arm of the trial, but no new safety signals were observed for the combination.
  • Please see Important Safety Information at the end of this news release for TUKYSA (tucatinib) tablets.

Global Antibody Drug Conjugate (ADC) Competitive Landscape Report 2023: Comprehensive Insights on More than 180 Companies and 290+ Pipeline Dugs - ResearchAndMarkets.com

Retrieved on: 
Friday, November 17, 2023
Health, Pharmaceutical, Acquisition, Antigen, Safety, Annual general meeting, Research, Toxicity, Spacecraft, Competition, Orange County Convention Center, ADC, Sanofi, FDA, Merck, Report, Seagen, Therapy, Endocytosis, Cancer, Antibody, Immunotherapy, ImmunoGen, Poster, Conjugation, AACR, NSCLC, Vaccine, Fine chemical, Pharmaceutical industry, Hong Kong

The "Antibody Drug Conjugate - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antibody Drug Conjugate - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about 180+ companies and 290+ drugs in Antibody Drug Conjugate Competitive landscape.
  • Antibody-drug conjugate (ADC) is a new emerging class of highly potent pharmaceutical drugs, which is a great combination of chemotherapy and immunotherapy.
  • The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends.

Envista Holdings Corporation Appoints Three New Members to Leadership Team

Retrieved on: 
Thursday, December 14, 2023
Human resources, Research, NYSE, Senior, AstraZeneca, Bank, Nobel Biocare, Gilead Sciences, Seagen, Kite Pharma, Envista Forensics, Global marketing, Information technology, JPMorgan Chase, M&A, Separation, Capital, Internal communications, Danaher Corporation, NVST, Bank of America, Management, Diagnosis, Cepheid variable, LATAM

Robert Befidi joins Envista from 3M, where he most recently was President of the Separation and Purification Sciences Division, a global filtration technology leader.

Key Points: 
  • Robert Befidi joins Envista from 3M, where he most recently was President of the Separation and Purification Sciences Division, a global filtration technology leader.
  • Suraj Satpathy joins Envista Holdings Corporation from Cepheid, a global diagnostics company under the Danaher Corporation, where he most recently served as the Senior Vice President of Human Resources and Internal Communications.
  • Amir Aghdaei, CEO Envista, is working directly with the Nobel Biocare leadership team to expand the business' capabilities and accelerate growth in 2024 until a permanent successor is named.
  • "Envista and our customers will benefit from the leadership and expertise of Robert, Andrew, and Suraj," said Amir.

Secura Bio Announces the Addition of Two New Board of Directors Members

Retrieved on: 
Thursday, December 7, 2023
Bayer, Executive Committee, Commercial, Hematology, Patient, Seagen, Standard of care, MD, S-1 Executive Committee, Dermatology, Genentech, Leo Pharma, Management

SUMMERLIN, Nev., Dec. 7, 2023 /PRNewswire/ -- Secura Bio, Inc. (Secura Bio) - ( www.securabio.com ), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announces that it has added two members to the board of directors of Secura Bio Holdings, Inc.

Key Points: 
  • SUMMERLIN, Nev., Dec. 7, 2023 /PRNewswire/ -- Secura Bio, Inc. (Secura Bio) - ( www.securabio.com ), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announces that it has added two members to the board of directors of Secura Bio Holdings, Inc.
  • The new members are Joerg Moeller, MD and Charles (Chip) R. Romp.
  • He was the former Head of Global Research and Development at Bayer Pharmaceuticals and a member of Bayer Pharma´s Executive Committee.
  • With his addition to the board, Chip Romp stated, "I am thrilled to join the board of directors and look forward to working with the company's leadership to improve the lives of patients".

Genmab Announces Financial Results for the First Nine Months of 2023

Retrieved on: 
Tuesday, November 7, 2023
Sale, BioNTech, Janssen, DKK, Novartis, Interim, USD, AbbVie, Patient, OS, Clothing, Pharmaceutical industry, Genmab, Health, Ofatumumab, Seagen

Revenue was DKK 11,796 million for the first nine months of 2023 compared to DKK 9,368 million for the first nine months of 2022.

Key Points: 
  • Revenue was DKK 11,796 million for the first nine months of 2023 compared to DKK 9,368 million for the first nine months of 2022.
  • Operating expenses were DKK 8,045 million in the first nine months of 2023 compared to DKK 5,676 million in the first nine months of 2022.
  • Operating profit was DKK 3,651 million in the first nine months of 2023 compared to DKK 3,692 million in the first nine months of 2022.
  • Net financial items resulted in income of DKK 1,060 million for the first nine months of 2023 compared to DKK 2,681 million in the first nine months of 2022.

Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Brentuximab vedotin, DCR, Society for Immunotherapy of Cancer, Pembrolizumab, Head, PD-1, Development, CD8, SITC, Immunotherapy, ADC, CD30, Inc., Clinical trial, Transportation Research Part E, Research and development, Annual general meeting, ORR, Seagen, RECIST, Tumor microenvironment, Lung cancer, Melanoma, Safety, Society, ADCETRIS, Patient, Toxicity, Neck, Pharmaceutical industry, Vaccine, NSCLC

The studies were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place November 3-5, 2023, in San Diego.

Key Points: 
  • The studies were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place November 3-5, 2023, in San Diego.
  • “The combination of ADCETRIS and a PD-1 inhibitor to treat solid tumors are intriguing and support continued research,” said Roger Dansey, M.D., President, Research and Development and Chief Medical Officer at Seagen.
  • The study design included melanoma patients who were treated in the study within 90 days of receiving prior anti-PD-1 therapy.
  • Preclinical data suggest that SGN-35T may be highly effective, like ADCETRIS, with the potential for improved tolerability.

ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment

Retrieved on: 
Thursday, November 2, 2023
Research, Thought Leadership, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, IPO, Pharmacyclics, Catalent, Alder, Therapy, Hematology, Nutcracker, MBS, Head, CMC, Seagen, Lundbeck, University of California, Acquisition, PTK7, Protein, Economics, Lundbeck Seattle Biopharmaceuticals, Yale University, Immunotherapy, Growth, SITC, ADC, Division, University, Biology, Amgen, Baxter International, Internal medicine, Merrill (company), Business, Keck Graduate Institute, Society for Immunotherapy of Cancer, Genentech, Society, Cancer, Seattle, University of Southern California, Coronavirus Scientific Advisory Board, Fine chemical, Management, Biochemistry, Proteolix, Chiron, Spacecraft, Western Washington University

We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.

Key Points: 
  • We are thrilled to welcome Erin and Kevin to our leadership team as we plan for this next stage of growth.
  • In addition, as chair of our Scientific Advisory Board, Lori brings decades of clinical thought-leadership and strategic product development experience in ADCs.
  • We look forward to working alongside them.”
    ProfoundBio also announced additional changes to the company's executive team.
  • Co-founders Tae Han and Xiao Shang will take on the roles of chief strategy officer and head of CMC, respectively.

New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate

Retrieved on: 
Thursday, November 2, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Brentuximab vedotin, Lymphoma, Society, Development, ASH, CHL, Hodgkin lymphoma, ADC, Inc., Research and development, Immunotherapy, Exposition, ADCETRIS, Patient, Pharmaceutical industry, Seagen

The data will be featured in two oral presentations at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 9-12, 2023 in San Diego.

Key Points: 
  • The data will be featured in two oral presentations at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 9-12, 2023 in San Diego.
  • The ongoing Phase 2 clinical trial, SGN35-027, is evaluating ADCETRIS in combination with immunotherapy and chemotherapy.
  • In addition, pre-clinical data will be presented for a next-generation novel CD30-directed antibody-drug conjugate (ADC), SGN-35C, that uses a topoisomerase I inhibitor payload.
  • ADCETRIS is a proven foundation of care for certain CD30-expressing lymphomas with more than 120,000 patients treated globally across seven indications.

Actinium Appoints Lynn Bodarky as Chief Business Officer

Retrieved on: 
Friday, November 3, 2023
ACT, Pharmacia, CRADA, Bone marrow, NCI, NYSE, Columbia Business School, Kite Pharma, Rare, Precigen, Vaccine, BS, Business development, Genetics, Seagen, Wharton School of the University of Pennsylvania, Merck, University, Acquisition, MBA, Prostate cancer, Pfizer, Novartis, Geron Corporation, Neuroscience, Business, Immunotherapy, NIH, Autoimmunity, PSMA, Patient, Marketing, Pharmaceutical industry, Methylnaltrexone, Actinium

NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that Lynn Bodarky has been named Chief Business Officer to lead the Company's business development, licensing, and collaboration activities. Ms. Bodarky joins Actinium with over 25 years of proven business development and licensing experience at large global pharmaceutical and innovative biotechnology companies including Pfizer, Merck, Progenics and HiFiBiO. Over her career, she has executed a wide array of business transactions totaling over $5 billion in value across oncology, autoimmune and neurological indications.

Key Points: 
  • NEW YORK, Nov. 3, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that Lynn Bodarky has been named Chief Business Officer to lead the Company's business development, licensing, and collaboration activities.
  • Ms. Bodarky joins Actinium with over 25 years of proven business development and licensing experience at large global pharmaceutical and innovative biotechnology companies including Pfizer, Merck, Progenics and HiFiBiO.
  • Ms. Bodarky joins Actinium from HiFiBiO Therapeutics, a clinical-stage biotechnology company developing immunotherapies for oncology and autoimmune diseases, where she was Senior Vice President, Global Head of Business Development & Operations.
  • "I am incredibly excited to join Actinium given the numerous near- and longer-term business development opportunities.

Global ADC (Antibody Drug Conjugates) Market Research Report 2023-2035: Focus on ADC Linker and ADC Conjugation Technologies - Over 420 ADCs are Currently Being Evaluated - ResearchAndMarkets.com

Retrieved on: 
Monday, October 23, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Conjugation, USFDA, Biomarker, DAR, Seagen, Research, Engineering, ADC, Neoplasm, Zymeworks, Spacecraft, Partnership, Generation, Overalls, Safety, Toxicity, Fine chemical, Vaccine, Linker, Gemtuzumab ozogamicin

The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at compounded annual growth rate (CAGR) of ~15% during 2023-2035.

Key Points: 
  • The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at compounded annual growth rate (CAGR) of ~15% during 2023-2035.
  • The challenges associated with conventional drug products have led to the development of advanced ADC linker and ADC conjugation technologies.
  • The ADC technologies market landscape features an extensive list of over 65 large, mid-sized and small companies that offer more than 95 ADC linker and conjugation technologies.
  • These platforms include linker technologies, linker-payload technologies and antibody conjugation technologies for the development of ADC.